Oxford-AstraZeneca Vaccine for COVID-19: A Case Report COVID-19
Journal of Cellular & Molecular Anesthesia,
Vol. 6 No. 4 (2021),
21 Bahman 2022
,
Page 346-351
https://doi.org/10.22037/jcma.v6i4.34860
Abstract
The design and development of a vaccine against the new coronavirus obtain an important goal of the global health community, which has developed and approved several vaccines, including the Oxford-AstraZeneca vaccine. The vaccine has been challenged because of reports of side effects after vaccination, while the level of immunity created by the vaccine has been confirmed. In this study, we examined the complication and change in laboratory tests of hematology, biochemistry, and enzymology in a 42-year-old woman with no history of specific disease after receiving the Oxford-AstraZeneca vaccine for 7 days. Our studies showed that following the injection of the vaccine, platelet, RBC, WBC decreased, and increased D-Dimer rates. Also that the standard rate has changed between Neutrophil, Lymphocyte, and Monocyte. There is evidence of Prothrombotic Immune Thrombocytopenia and following that there is a risk of the embolism, but the particular point is that this complication is temporary and the test process is progressing towards recovery.
- Oxford-AstraZeneca, COVID-19, Vaccine
How to Cite
References
Pooladi M, Hushmandi K, Entezari M. Risk of increased expression of ACE2 membrane protein in patients with hypertension: Review of COVID-19. Arch Adv Biosci. 2021;12(1):52-64.
Pooladi M, Entezari M, Hashemi M, Bahonar A, Hushmandi K, Raei M. Investigating the Efficient Management of Different Countries in the COVID-19 Pandemic. J Mar Med. 2020;2(1):18-25.
Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: The current state of play. Paediatr Respir Rev. 2020;35:43-9.
Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021;138(4):350-3.
Garnier M, Curado A, Billoir P, Barbay V, Demeyere M, Dacher JN. Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia. Diagn Interv Imaging. 2021;102(10):649-50.
Khaldi A, Helo N, Schneck MJ, Origitano TC. Venous thromboembolism: deep venous thrombosis and pulmonary embolism in a neurosurgical population. J Neurosurg. 2011;114(1):40-6.
Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 2021;397(10283):1441-3.
Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et al. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. Clin Infect Dis. 2021.
Mahase E. How the Oxford-AstraZeneca covid-19 vaccine was made. BMJ. 2021;372:n86.
Pimenta D, Yates C, Pagel C, Gurdasani D. Delaying the second dose of covid-19 vaccines. BMJ. 2021;372:n710.
Dyer O. Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts. BMJ. 2021;373:n883.
Boytchev H. Why did a German newspaper insist the Oxford AstraZeneca vaccine was inefficacious for older people-without evidence? BMJ. 2021;372:n414.
Boytchev H. Covid-19: Germany struggles with slow uptake of Oxford AstraZeneca vaccine. BMJ. 2021;372:n619.
Hunter PR. Thrombosis after covid-19 vaccination. BMJ. 2021;373:n958.
Riad A, Schünemann H, Attia S, Peričić TP, Žuljević MF, Jürisson M, et al. COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines' Side Effects. Int J Environ Res Public Health. 2021;18(15).
Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1469-72.
Mahase E. AstraZeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. BMJ. 2021;373:n931.
Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133(2):309-14.
Fraser JL, Millenson M, Malynn ER, Uhl L, Kruskall MS. Possible association between the Norplant contraceptive system and thrombotic thrombocytopenic purpura. Obstet Gynecol. 1996;87(5 Pt 2):860-3.
Bartholomew JR, Schaffer JL, McCormick GF. Air travel and venous thromboembolism: minimizing the risk. Cleve Clin J Med. 2011;78(2):111-20.
Jemielniak D, Krempovych Y. An analysis of AstraZeneca COVID-19 vaccine misinformation and fear mongering on Twitter. Public Health. 2021;200:4-6.
- Abstract Viewed: 156 times
- PDF Downloaded: 132 times